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Abstract
The mammalian type I gonadotropin releasing hormone receptor (GnRH-R) is a structurally unique G protein-coupled
receptor (GPCR) that lacks cytoplasmic tail sequences and displays inefficient plasma membrane expression (PME).
Compared to its murine counterparts, the primate type I receptor is inefficiently folded and retained in the endoplasmic
reticulum (ER) leading to a further reduction in PME. The decrease in PME and concomitant increase in intracellular
localization of the mammalian GnRH-RI led us to characterize the spatial distribution of the human and mouse GnRH
receptors in two human cell lines, HEK 293 and HTR-8/SVneo. In both human cell lines we found the receptors were
expressed in the cytoplasm and were associated with the ER and nuclear membrane. A molecular analysis of the receptor
protein sequence led us to identify a putative monopartite nuclear localization sequence (NLS) in the first intracellular loop
of GnRH-RI. Surprisingly, however, neither the deletion of the NLS nor the addition of the Xenopus GnRH-R cytoplasmic tail
sequences to the human receptor altered its spatial distribution. Finally, we demonstrate that GnRH treatment of nuclei
isolated from HEK 293 cells expressing exogenous GnRH-RI triggers a significant increase in the acetylation and
phosphorylation of histone H3, thereby revealing that the nuclear-localized receptor is functional. Based on our findings, we
conclude that the mammalian GnRH-RI is an intracellular GPCR that is expressed on the nuclear membrane. This major and
novel discovery causes us to reassess the signaling potential of this physiologically and clinically important receptor.
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Introduction
The gonadotropin releasing hormone receptor (GnRH-R) is a
G protein-coupled receptor (GPCR) belonging to the rhodopsin
family. In mammals, the type I receptor (GnRH-RI) is expressed
in a variety of cell-types including pituitary gonadotropes, T-cells
and placental cytotrophoblasts [1,2]. Ligand-activated GnRH-RI
couples to several different G proteins, including Gq/11,G s and Gi
[1,3–5]. In humans, GnRH-RI is located at 4q13.1–q21.1 and
consists of three exons and two introns that encode a 328 amino
acid protein [6,7].
The mammalian type I GnRH-R is structurally unique among
GPCRs, including other GnRH-Rs expressed in non-mammalian
and some primate species, in that it does not possess an
intracellular tail [6]. The absence of COOH-tail sequences may
have resulted in a receptor that lacks sequences necessary for
mediating rapid desensitization and internalization as well as
strong plasma membrane expression (PME) [8]. In addition, based
on biochemical studies (radioligand binding and inositol phosphate
formation assays) performed in African Green Monkey Kidney
Fibroblast Cells (COS-1) and Human Embryonic Kidney (HEK
293) cells, it has been demonstrated that the presence of a primate-
specific lysine residue at position 191 (K191) in the human GnRH-
RI contributes to increased internalization kinetics of the receptor,
leading to an overall reduction in PME compared to its rat and
mouse counterparts [9,10]. The presence of this primate-specific
K191 has been suggested to cause the disruption of a sulfhydryl
bridge and subsequent formation of misfolded receptors resulting
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[11]. The loss of cytoplasmic tail sequences coupled to the
presence of K191 are believed to be the result of a recently evolved
strategy that has led to decreased PME and greater intracellular
localization of GnRH-RI. This strategy provides the cell a very
effective mechanism for rapidly regulating cell surface receptor
number and hence GnRH-RI-mediated cell signaling events [11].
It is believed that the ER-retained misfolded receptors are
eventually degraded by the cell’s quality control system [11]. It has
also been suggested that part of this retained intracellular pool of
receptor provides a source of GnRH-RI needed for rapid
availability to the cell without the need for transcription or
translation [11]. In addition to these suggestions, we propose that
in cells which express both the receptor and ligand, greater
intracellular localization of GnRH-RI is perhaps an indication that
the cell is evolving towards greater intracrine signaling. To pursue
these ideas further, we undertook a detailed spatial and functional
characterization of the intracellular receptor. Here we report the
human and mouse FLAG-GnRH receptors are expressed
intracellularly in two human cell lines, with strong localization to
the nuclear membrane. Finally, we also demonstrate that the
nuclear membrane localized human GnRH-RI is functional and
that receptor stimulation triggers a robust increase in histone H3
acetylation and phosphorylation. These findings reveal that
GnRH-RI is a member of a small but growing class of functional
nuclear GPCRs and reveals the existence of an entirely novel facet
to GnRH-RI signaling within the cell.
Results
Preliminary biochemical and spatial analyses of FLAG-
hGnRH-RI
The HEK 293 cell line is an established cell system for studying
regulatory, temporal and spatial characteristics of GPCRs [12–14]
and based on RT-PCR analysis does not express GnRH-RI (data
not shown). HTR-8/SVneo is a trophoblast cell line that is an
established system for studying human placentation [2,15] and
previous studies from our lab and elsewhere have demonstrated
that trophoblasts, including HTR-8/SVneo cells, express GnRH-
RI [1,2]. In the absence of effective anti-GnRH-RI antibodies we
could not examine the spatial distribution of endogenous GnRH-
RI in these cells; consequently, we constructed a FLAG amino
terminus epitope-tagged receptor (open-reading frame only) for
this purpose. Before using this construct to assess the spatial and
functional properties of GnRH-RI in these cell lines, the signaling
capacity of FLAG-hGnRH-RI was compared to that of an
untagged hGnRH-RI cDNA (accession number NM_000406.2).
Our data revealed that Buserelin, a metabolically stable GnRH
agonist, stimulated similar levels of inositol phosphate (IP)
formation by both FLAG-hGnRH-RI- and hGnRH-RI cDNA-
expressing HEK 293 cells (Fig. 1A) suggesting that the FLAG
epitope does not alter the signaling potential of the receptor. Next,
through an immunofluorescence analysis of the FLAG-hGnRH-
RI we observed that the receptor was strongly localized
intracellularly with a clear perinuclear distribution (Fig. 1B).
Immunostaining of non-transfected cells with the FLAG primary
and Alexa Fluor 568-conjugated anti-rabbit IgG secondary
antibodies yielded unstained cells, suggesting that the perinuclear
localization of FLAG-hGnRH-RI is not an artifact of immuno-
staining (data not shown). Since our spatial analysis thus far was by
indirect immunofluorescence (directed against the FLAG epitope),
we analyzed the spatial distribution of the hGnRH-RI-GFP
chimeric molecule by direct fluorescence and found that this
molecule was also strongly distributed in a perinuclear manner
(Fig. 1B). This suggested that the perinuclear distribution of
FLAG-hGnRH-RI is unlikely the effect of the FLAG epitope.
Based on these findings we selected the FLAG-tagged GnRH-RI
(human and mouse) for all subsequent studies. The FLAG-GnRH-
RI DNA was introduced into HEK 293 cells by calcium-
phosphate transfection, while it was introduced into HTR-8/
SVneo cells by electroporation. Transfection efficiency of the
HEK 293 cells was always greater than 75%, while that for HTR-
8/SVneo cells was closer to 25% (data not shown).
Spatial characterization of GnRH-RI in HEK 293 and HTR-
8/SVneo cells
Immunofluorescence studies performed on agonist (Buserelin)
treated and untreated Triton X 100-permeabilized cells, using the
anti-FLAG antibody clearly revealed that the spatial localization of
FLAG-hGnRH-RI is identical in both HEK 293 and HTR-8/
SVneo cells (Fig. 1C) and that agonist stimulation did not affect the
cellular distribution (Fig. 1C). The presence of the receptor was
visually undetectable at the plasma membrane but was strongly
localized intracellularly in 100% of the transfected cells. While the
receptor was distributed intracellularly throughout the cell there
were two intracellular regions in which expression was very high.
In 100% of all transfected cells, one region corresponded to a large
part of the cytoplasm, generally located to one side of the nucleus
only, while in about 75–95% of these cells, the receptor was also
strongly observed at the perinuclear region (Fig. 1C). To test the
possibility that the perinuclear-localized receptor was a misloca-
lized truncated molecule, we western-blotted lysates of nuclei
isolated from HEK 293 cells overexpressing FLAG-GnRH-RI and
observed that it is in fact the full-length receptor that is expressed
and localized to this region (Fig. 1D).
To characterize the spatial localization of the receptor in greater
detail we examined the location of the receptor relative to
calnexin, GM130 and lamin A/C; these are organellar markers for
the ER, Golgi and the nuclear membrane, respectively. Our
results revealed that a large fraction of the cytoplasmic pool of
receptors localized to the ER (Fig. 1E) while the perinuclear pool
localized to the nuclear membrane (Fig. 1E). Receptor localization
to the Golgi was also visually detectable, however, not as readily as
it was in the ER (Fig. 1E). In all cases no differences were observed
between the HEK 293 and HTR-8/SVneo cells (Fig. 1E). Since
we consistently showed no differences in the localization of the
receptor in the two cell lines most of the spatial studies were
conducted in the HTR-8/SVneo cell line only.
Spatial characterization of GnRH-RI, compared to
mGluR5a and b2AR, in HTR-8/SVneo cells
Next, we compared the distribution pattern of FLAG-hGnRH-
RI in HTR-8/SVneo cells to that of FLAG-mGluR5a (metabo-
tropic glutamate receptor 5a) and FLAG-b2AR (b2-adrenergic
receptor) in HTR-8/SVneo cells (Fig. 2A). Both receptors are
GPCRs and mGluR5a has been well characterized as a nuclear
GPCR that is expressed on the nuclear membrane [16,17] while
the b2AR has only been detected on the plasma membrane and in
the cytoplasm [18,19]. Immunofluorescence studies on agonist
(quisqualate for mGluR5a and isoproterenol for b2AR) treated
cells permeabilized prior to their incubation in anti-FLAG
antibody revealed that mGluR5a colocalized with lamin A/C at
the nuclear membrane in a pattern identical to that of hGnRH-RI
and lamin A/C, while as expected, b2AR was strongly expressed
at the plasma membrane (Fig. 2A). b2AR and mGluR5a were also
seen intracellularly on vesicles as well as evenly distributed
throughout the rest of the cytoplasm. However, unlike mGluR5a,
GnRH-RI, a Nuclear GPCR
PLoS ONE | www.plosone.org 2 July 2010 | Volume 5 | Issue 7 | e11489Figure 1. Effect of epitope tag on hGnRH-RI signaling and spatial localization of FLAG-hGnRH-RI. (A) Inositol phosphate (IP) production
in response to 100 nM Buserelin was assessed as described in ‘‘Materials and Methods’’. Data represent three to six independent experiments
performed in triplicate and normalized to FLAG-hGnRHRI 6 S.E. (B, left) HTR-8/SVneo cells transfected with either FLAG-hGnRH-RI (a) subjected to
indirect immunofluorescent staining using affinity purified rabbit anti-FLAG antibody followed by Alexa Fluor 568-conjugated anti-rabbit IgG (red)
and counterstained with the nuclear dye, Hoechst (blue). Note the perinuclear localization of the FLAG-tagged hGnRH-RI (a, arrow); (B, right) HTR-8/
SVneo cell transfected with GnRH-RI-GFP and counterstained with the nuclear dye, Hoechst (blue). Note the perinuclear localization of the GnRH-RI-
GFP. (C) HTR-8/SVneo and HEK 293 cells transfected with FLAG-hGnRH-RI were subjected to indirect immunofluorescent staining using affinity
purified rabbit anti-FLAG antibody followed by Alexa Fluor 568-conjugated anti-rabbit IgG (red) and counterstained with Hoechst (blue). Note the
perinuclear localization of the FLAG-tagged hGnRH-RI seen in both cell lines (arrows). Bright field images are shown in the second column from the
left. (D) Western blot analysis was performed on the lysates of nuclei isolated from HEK 293 cells overexpressing FLAG-GnRH-RI. The results reveal that
the full length hGnRH-RI is expressed on the nuclei of HEK 293 cells. (E) Cells expressing FLAG-hGnRH-RI were subjected to indirect
immunofluorescent staining for the receptor (red) as well as the nuclear membrane, endoplasmic reticulum and Golgi (all shown in green).
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ingly, unlike FLAG-mGluR5a and FLAG-b2AR, the cytoplasmic
distribution of FLAG-hGnRH-RI was often more strongly
localized to one side of the nucleus, rather than throughout the
cell (Fig. 2A). To test whether the differences in the spatial
distribution were in part due to relative expression levels between
Colocalization is seen as yellow staining. Column A: receptor alone; Column B: receptor + Hoescht; Column C: organelle marker (lamin A/C, calnexin or
GM130) + Hoescht; Column D: receptor + organelle marker. Column letters and roman numerals used as a coordinate system. hGnRH-RI
immunoreactivity co-localized with the nuclear marker, lamin A/C, as seen by the yellow staining (I-D, II-D, arrows) as well as with the endoplasmic
reticulum marker, calnexin (III-D, IV-D). Less colocalization was seen between the receptor and the Golgi, as shown by less yellow staining (V-D, VI-D).
Scale bar=10 mm.
doi:10.1371/journal.pone.0011489.g001
Figure 2. Spatial localization of FLAG-mGluR5a, FLAG-b2AR and FLAG-hGnRH-RI. (A) HTR-8/SVneo cells transfected with either FLAG-
mGluR5a or FLAG-b2AR were subjected to indirect immunofluorescent staining for the receptor (red) as well as the nuclear membrane marker lamin
A/C (green). Cells were counterstained with Hoechst (blue). Note the perinuclear localization of the FLAG-tagged mGluR5a (arrow) and the plasma
membrane localization of both FLAG-mGluR5a and FLAG-b2AR (arrowheads). Bright field images are shown in the second row from top. (B) Isolated
nuclei from HEK293 cells expressing FLAG-hGnRH-RI, FLAG-mGluR5a or FLAG-b2AR were subjected to indirect immunofluorescent staining for the
receptor (red) as well as the nuclear membrane marker lamin A/C (green). Cells were counterstained with Hoechst (blue). Note the colocalization of
both FLAG-hGnRH-RI and FLAG-mGluR5a with the inner nuclear membrane marker lamin A/C (yellow, arrows). FLAG-b2AR was not localized to the
nuclear membrane. Bright field images are shown in the second row from top. Scale bar=10 mm.
doi:10.1371/journal.pone.0011489.g002
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of receptor gene expression in HEK 293 cells and found that all
the receptors were expressed at similar levels (data not shown),
suggesting that differential expression is not the underlying cause
for these observations.
Spatial characterization of GnRH-RI on isolated nuclei
In addition to looking at the localization of GnRH-RI in whole
cells, we also performed immunolocalization studies on intact
nuclei isolated from HEK 293 cells that were previously
transfected with FLAG-hGnRH-RI or FLAG-mGluR5a. The
purpose of these studies was to determine whether the apparent
nuclear localization of hGnRH-RI was real or was a visual
aberration due to the result of hGnRH-RI being overexpressed at
the perinuclear region. If this were the case, it was possible that
lamin A/C might have only appeared to colocalize with the pool
of receptor molecules in the adjoining perinuclear region. Thus by
stripping away the cytoplasmic pool of receptor, we could more
confidently assess receptor localization on the nuclear membrane.
The results from these experiments revealed that in the absence of
the cytosolic components, as confirmed by visual inspection and a
lack of Golgi and ER staining, both FLAG-hGnRH-RI and
FLAG-mGluR5a were still strongly detectable at the nuclear
membrane and colocalized with lamin A/C (Fig. 2B). Further-
more, an analysis of nuclei isolated from cells expressing FLAG-
b2AR did not show any receptor on the nuclear membrane
(Fig. 2B). These results strongly demonstrate that the nuclear
membrane localization of hGnRH-RI is real and not the result of
a visual aberration due to overexpression of the receptor in the
perinuclear region.
Characterization of NLS located in GnRH-RI protein
sequence
Both the strong colocalization of hGnRH-RI and lamin A/C in
HEK 293 and HTR-8/SVneo cells (Fig. 1F) and the identical
pattern of colocalization observed to that of the nuclear mGluR5a
and lamin A/C in HTR-8/SVneo cells (Fig. 2A) suggested that
hGnRH-RI might be a nuclear GPCR associated with the nuclear
membrane. This possibility led us to examine the protein sequence
of hGnRH-RI for a putative nuclear localization signal (NLS).
Using the Basic Local Alignment Search Tool (BLAST) to search
for short nearly exact matches in the National Centre for
Biotechnology Information protein database, we identified a
putative monopartite NLS sequence, KKEKGKK (amino acid
position 66–72) (Fig. 3A, Table 1). This sequence was conserved in
other proteins characterized as nuclear localized proteins (Table 1).
These include DNA topoisomerase II from Candida spp.,
pleiotrophic factor a2 (transcriptional regulator) from Xenopus
laevis, HAI-2 related small protein (transcriptional regulator) from
humans, and a number of other proteins from various species with
putative nuclear functions such as the putative U3 small nuclear
ribonucloprotein (snRNP) from Leishmania major. Next, using the
DNASTAR Lasergene MegAlign program, we performed protein
sequence alignments and observed that this sequence is fully
conserved in the GnRH-RI protein expressed in the chimpanzee
while in the mouse and rat, five of the seven residues in the
primate sequence are found at the equivalent site (Table 1). This
murine sequence (KRKKGKK), however, still contains a fully
conserved monopartite NLS. A stretch of highly basic amino acid
residues is also found in the chicken GnRH receptor (RKRRK) at
the equivalent region in the first intracellular loop (Fig. 3A,
Table 1), however, similar sequences are not located in any part of
the mammalian type II GnRH-R (data not shown), a receptor that
appears to be activated only by the type II GnRH.
NLS deletion analysis: determining the effect on GnRH-RI
spatial localization
To test whether the putative NLS located in the first
intracellular loop of hGnRH-RI was required for the nuclear
localization of the receptor, we performed single and multiple
amino acid substitutions (mutating K and E to the non-charged G
residue) and deletions as well as a full deletion of the KKEKGKK
sequence in FLAG-hGnRH-RI and expressed the mutant receptor
in HTR-8/SVneo cells. Surprisingly, we found that none of the
mutations, including the full KKEKGKK deletion mutant, altered
the spatial distribution of the receptor or frequency of cells
expressing the receptor on the nuclear membrane (as assessed by
lamin A/C colocalization) relative to the non-mutated receptor
(Fig. 3B, data shown for the full putative NLS deletion mutant
only). Interestingly, we found that although the full putative NLS
deletion mutant still localized to the nuclear membrane, it showed
a significantly diminished capacity to stimulate IP formation (in
HEK 293 cells) following agonist treatment relative to its wild-type
counterpart (Fig. 3C).
K191 mutational analysis: determining the effect on
GnRH-RI spatial localization
Next, based on previous data which revealed that the presence
of a primate specific-residue, K191, in the hGnRH-RI contributed
to an overall reduced PME, we investigated whether this residue
also regulated nuclear membrane localization of hGnRH-RI. Our
studies revealed that neither mutating the basic lysine residue to
the acidic glutamic residue (E) nor deleting K191 led to any visual
change on the cellular distribution of the receptor, particularly
with respect to its nuclear membrane localization (Fig. 3D). This
observation was further supported by IP formation data which
revealed that there was no significant difference between the
mutants, K191E and K191 deletion, compared to the wild-type
FLAG-tagged human receptor. Nevertheless, both mutants
showed a trend towards an increase in IP formation relative to
the non-mutated receptor (Fig. 3E).
Spatial characterization of the mouse GnRH-RI in HEK 293
and HTR-8/SVneo cells
Since the murine receptor lacks the K191 residue but contains a
fully conserved monopartite NLS in the homologous position to
the human NLS, we looked at the localization of the mouse
FLAG-GnRH-RI in HEK 293 and HTR-8/SVneo cells. Our
studies revealed that in both cell types, the mouse receptor was
also expressed on the nuclear membrane (Fig. 3F, HEK 293 data
not shown) like its hGnRH-RI counterpart (Fig. 1F). However,
unlike the hGnRH-RI, the mGnRH-R was localized throughout
the cytoplasm, and was weakly detected at the plasma membrane
(Fig. 3F).
Spatial characterization of the human-Xenopus GnRH-RI
and Xenopus GnRH-RI in HEK 293 and HTR-8/SVneo cells:
determining the effect of cytoplasmic tail sequences on
GnRH-RI spatial localization
To further explore the molecular determinants of GnRH-RI
nuclear membrane localization, we assessed the contribution of
cytoplasmic tail sequences to spatial localization. To conduct these
studies we expressed the FLAG-tagged full-length Xenopus GnRH-
RI and a FLAG-tagged chimeric human-Xenopus C-tail construct
in both HEK-293 and HTR-8/SVneo cells and determined their
spatial localization. Our findings revealed that in both cell types in
the absence and presence of agonist, the chimeric GnRH-RI
sequences displayed a nuclear localization pattern identical to the
GnRH-RI, a Nuclear GPCR
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found in greater than 95% of all cells (Table 2, Fig. 4) expressing
the chimeric construct. Interestingly, however, when the full-
length wild-type Xenopus sequences were expressed, the receptor
was mainly found at the plasma membrane and evenly distributed
intracellularly with less than 5% of the cells showing any nuclear
localization (Table 2, Fig. 4). This was consistent for both cell types
in the presence and absence of agonist.
The nuclear-localized GnRH-RI is functional
Once we were confident that the human and mouse GnRH-RI
were expressed at the nuclear membrane we determined whether
the nuclear membrane localized hGnRH-RI was functional. Since
these studies required a large number of nuclei we used HEK 293
cells since they were more efficiently transfected than the HTR-8/
SVneo cells. HEK 293 cells were transfected with hGnRH-RI and
nuclei were isolated under detergent-free conditions. Nuclei
integrity and purity were determined visually and by immuno-
blotting for subcellular markers. These analyses confirmed that
nuclei preparations of very high integrity and purity were obtained
using our isolation method (Fig. 5A). Based on recent studies that
show the nuclear bradykinin B2 receptor is functionally coupled to
histone acetylation [20] we assayed for GnRH stimulated histone
H3 acetylation and found that GnRH triggered a significant
increase in acetylation following 15 and 30 minutes of stimulation
(Fig. 5B). We then assayed for H3 phosphorylation and also found
that GnRH triggered a significant increase in phosphorylation
following 5, 15 and 30 minutes of stimulation (Fig. 5B).
Discussion
It has been almost three decades since Millar’s laboratory
demonstrated the presence of the GnRH receptor on rat anterior
pituitary nuclei through the use of radiolabeled GnRH agonists
[21] and about a decade since Conn’s laboratory proposed the
idea that the GnRH receptor has evolved towards reduced plasma
membrane expression [8]. Additionally, there have been at least
four other studies that provide evidence that GnRH-R is
detectable at the nucleus. Following Millar’s findings in 1983,
Morel et al. [22] in 1987 demonstrated that extensive radiolabeled
GnRH accumulated over the nucleus and nuclear membrane of
radioligand treated rat gonadotrophs. The assumption was that
the label was bound to the rat GnRH-R at these sites.
Subsequently, in an immunohistochemical analysis of ligand
treated hamster pancreatic cancer cells, Szende et al. [23]
demonstrated that GnRH-R accumulated in the nucleus. In cell
fractionation studies using human breast cancer tissue Mangia et
al. [24] demonstrated that GnRH-R was associated with the
nuclear compartment while more recently, Meethal et al. [25]
demonstrated through immunohistochemical studies that in the
nematode C. elegans, GnRH-R was located in the nucleus. These
studies provided evidence that endogenously expressed GnRH-R
from the rat, hamster, nematode and human was detectable at the
Table 1. Proteins containing a putative monopartite NLS related to that found in the human gonadotropin releasing hormone
receptor isoform 1.
Definition Accession Sequence Amino Acid Position
Gonadotropin releasing hormone receptor isoform 1 [Homo sapiens] NP_000397 KKEKGKK 66–72
U3 small nuclear ribonucloprotein (snRNP) [Leishmania infantum JPCM5] XP_001466980 KKEKGKK 235–241
Type II DNA topoisomerase [Candida tropicalis] BAB13749 KKEKGKK 288–294
Pleiotrophic factor-alpha1 [Xenopus laevis] BAA07658 KKEKGKK 25–31
Alkylbase DNA N-glycosylase [Cryptococcus neoformans var. neoformans JEC21] XP_570311 KKEKGKK 723–729
HAI-2 related small protein [Homo sapiens] AAG43574 KKEKGKK 95–101
Gonadotropin releasing hormone receptor isoform 1 [Pan troglodytes] XP_001163813 KKEKGKK 66–72
Gonadotropin releasing hormone receptor [Mus musculus] NP_034453 KRKKGKK 66–72
Gonadotropin releasing hormone receptor [Rattus norvegicus] NP_112300 KRKKGKK 66–72
Gonadotropin releasing hormone receptor [Gallus gallus] NP_989984 RKRRK 69–73
doi:10.1371/journal.pone.0011489.t001
Figure 3. Effect of putative NLS and lysine 191 hGnRH-RI mutants on receptor localization and signaling and spatial localization of
FLAG-mGnRH-RI in HTR-8/SVneo cells. (A) Schematic of the human GnRH-RI showing the positions of the lysine 191 residue (triangle) and the
location of the putative NLS (square). (B) HTR-8/SVneo cells expressing FLAG-hGnRH-RI in which the putative NLS was deleted were subjected to
indirect immunofluorescent staining for the receptor (red) as well as the markers for the nuclear membrane, endoplasmic reticulum and Golgi (shown
in green). Cells were counterstained with Hoechst (blue). The NLS deletion mutant showed the same phenotype as the wild-type receptor, showing
strong colocalization with lamin A/C and calnexin and less colocalization with GM130. (C) IP formation data represent seven independent
experiments performed in triplicate and normalized to FLAG-hGnRHRI 6 S.E. ***, p,0.001 versus IP formation of FLAG-hGnRH-RI. (D) HTR-8/SVneo
cells expressing FLAG-hGnRH-RI in which lysine 191 was deleted or mutated to a glutamic acid residue (K191E) were subjected to indirect
immunofluorescent staining for the receptor (red) as well as the markers for the nuclear membrane, endoplasmic reticulum and Golgi (shown in
green). Cells were counterstained with Hoechst (blue). K191 deletion and K191E mutants showed the same phenotype as the wild-type receptor,
showing strong colocalization with lamin A/C and calnexin and less colocalization with GM130. (E) IP formation data represent 6–7 independent
experiments performed in triplicate and normalized to FLAG-hGnRHRI 6 S.E. (F) HTR-8/SVneo cells expressing mGnRH-RI were subjected to indirect
immunofluorescent staining for the receptor (red) as well as the markers for the nuclear membrane, endoplasmic reticulum and Golgi (shown in
green). Cells were counterstained with Hoechst (blue). FLAG-mGnRH-RI showed similar perinuclear localization (arrows) to FLAG-hGnRH-RI with strong
colocalization with lamin A/C and less colocalization with GM130. However, less colocalization was seen between the FLAG-mGnRH-RI and calnexin
than was seen with the FLAG-hGnRH-RI. As well, there was evidence of plasma membrane localization (arrowheads) with FLAG-mGnRH-RI that was
not seen with FLAG-hGnRH-RI. Bright field images are shown in the second row from top. Scale bar=10 mm.
doi:10.1371/journal.pone.0011489.g003
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could not allow for conclusive proof that the receptor is nuclear.
Furthermore, they provided no evidence that the nuclear-localized
GnRH-R is functional. Nevertheless, they do provide support for
our findings which clearly reveal that the human and mouse
GnRH-RI are expressed strongly at the nuclear membrane.
Our spatial observations are consistent with those previously
reported by Sedgley et al. [26] who also observed that in
mammary (MCF7) cells the wild-type human GnRH-RI is
inefficiently expressed at the plasma membrane. Our study is also
consistent with previous biochemical data [8,11,27–31] that
suggest both the wild-type and naturally occurring mutant human
GnRH-RI are expressed inefficiently at the plasma membrane and
are retained intracellularly, both in the presence and absence of
agonist. The mouse homologue is also expressed at similar levels in
both cell lines and our spatial data again support previous
biochemical data that reveal, unlike the mouse receptor, a large
fraction of the human receptor is retained in the ER [9,10,27].
Both the human and mouse receptors additionally show marked
expression at the nuclear membrane as revealed by colocalization
with lamin A/C. Lamin A/C, a type V nuclear lamin, is an
Intermediate Filament protein that is a component of the nuclear
lamina, a fibrous layer on the nucleoplasmic side of the inner
nuclear membrane which is suggested to provide a framework for
the nuclear envelope and may interact with chromatin. Addition-
ally, both receptors are also expressed at other intracellular sites;
weakly in the Golgi and strongly in the ER. Brothers et al. [32]
recently demonstrated through immunoprecipitation assays that
human GnRH-RI physically interacts with calnexin in COS-7
cells, where it is suggested to retain misfolded receptor molecules
while routing correctly folded molecules to the plasma membrane.
The observation that hGnRH-RI is inefficiently expressed at the
plasma membrane and strongly expressed intracellularly is
proposed to be the result of a progressive and convergent
evolutionary trend of the GnRH-R [11]. Potentially, intracellular
retention of the receptor creates and provides a source of GnRH-
RI needed for rapid availability without transcription or
translation. A similar mechanism might also regulate the human
d opioid receptor since a study by Peta ¨ja ¨-Repo et al. [33]
demonstrated that permeable agonists and antagonists of the
receptor allowed post-translational processing and increased
export of the ligand-stabilized receptor from the ER to the cell
surface. Other reports indicate that receptors such as GluR1, a1D
adrenoreceptor, odorant and luteinizing hormone receptors are
also inefficiently expressed at the plasma membrane [34–38], thus
suggesting that reduced receptor trafficking may represent a more
widespread mechanism for regulating protein availability [11]. In
this study we suggest that the mammalian GnRH-R is evolving
towards greater intracrine signaling in cells that express both the
receptor and ligand, such as the HTR-8/SVneo. Intracrine
signaling would appear to offer the cell more efficient and rapid
control of a signaling pathway. This is in contrast to autocrine
signaling which emanates at the plasma membrane, incorporates
additional signaling steps and may require more energy only to
eventually culminate in the same final cellular response as a
pathway that was initiated intracellularly.
To date, there is an increasing number of GPCRs identified as
nuclear GPCRs [39] and perhaps the best characterized nuclear
localized GPCR is the angiotensin (AT1) receptor. The nuclear
localization of the AT1 receptor is induced by angiotensin II
[40,41] and studies have uncovered angiotensin II-binding sites in
the nucleus and have also demonstrated the angiotensin II-
induced transcription of renin and angiotensinogen mRNA [42].
Other GPCRs that are localized to the nucleus include the
prostaglandin EP1 [43], EP3, and EP4 receptors [44], parathyroid
hormone receptor [45,46], metabotropic glutamate mGluR1a and
5a receptors [16,17], endothelin ETA and ETB receptors [47],
apelin and bradykinin (B2) receptors [48]. Some of these receptors
are located in the nucleoplasm and/or at the nuclear membrane
[17].
The AT1 receptor was reported to traffic to cell nuclei by the
presence of an NLS sequence in its 8
th helix (membrane proximal
C-terminal sequences) [41]. Subsequently NLS sequences have
been identified in the majority of GPCRs observed to have nuclear
localization. NLS sequences identified in GPCRs are generally
found in the 8
th helix, however, in the apelin receptor it is located
in the third intracellular loop [48]. The human (KKEKGKK) and
mouse (KRKKGKK) GnRH-RI putative NLS sequences are
located in the first intracellular loop and form a stretch of basic
amino acid residues that contains the monopartite consensus
sequence K-K/R-X-K/R [49] which strongly resembles both well
established and putative NLS sequences identified in nuclear
localized proteins like DNA topoisomerase II from Candida spp.,
pleiotrophic factor a2 (transcriptional regulator) from Xenopus
laevis, HAI-2 related small protein (transcriptional regulator) from
humans, and a number of other proteins from various species with
putative nuclear functions such as the putative U3 small nuclear
ribonucloprotein (snRNP) from Leishmania major.
Based on the presence of this sequence in proteins with
established nuclear function, we hypothesized that the human and
mouse GnRH-RI contained a functional NLS. However,
mutagenesis studies revealed that in both HEK 293 and HTR-
8/SVneo cells, the hGnRH-RI mutant lacking the KKEKGKK
sequence was still strongly expressed at the nuclear membrane.
This observation leads us to consider that this is not the functional
NLS or that it might not be the only NLS, thus its deletion may
not be sufficient to disrupt nuclear membrane localization. Also, it
is possible that while this is the NLS, additional flanking residues
must be deleted to disrupt localization. Finally, we must consider
that nuclear membrane localization is NLS-independent. Since the
hGnRH-RI is found on the nuclear membrane, as opposed to
within the nucleoplasm an NLS may not be required. This idea is
supported by evidence suggesting that the endothelin receptor
subtypes A and B, which have a perinuclear distribution, localize
to the nuclear membrane via de novo synthesis and retrograde
transport [47]. Further investigations are required to test whether
this mechanism accounts for hGnRH-RI localization at the
nuclear membrane.
To further explore the regulation of hGnRH-RI nuclear
localization, we examined the spatial localization of the human-
Xenopus C-tail chimeric GnRH-RI and full-length Xenopus GnRH-
RI in HEK 293 and HTR-8/SVneo cells. Our results revealed
that the full-length Xenopus receptor, in the absence of any human
sequences, was hardly detected at the nuclear membrane but
Table 2. Frequency of subcellular distribution of human-
Xenopus chimeric GnRH-R (HX-GnRH-R) and full-length
Xenopus GnRH-R (X-GnRH-R) in HEK 293 cells as assessed by
confocal microscopy.
Receptor
Plasma
Membrane (%)
1
Nuclear
Membrane (%)
1 ER (%)
1
HX-GnRH-R 0 97 100
X-GnRH-R 100 4 0
1Data based on the examination of 100 cells expressing each receptor subtype.
doi:10.1371/journal.pone.0011489.t002
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that nuclear localization is strongly determined by sequences in the
human receptor. It is possible that these sequences are poorly
conserved in the Xenopus receptor, thus, the receptor is infrequently
expressed at the nuclear membrane. It also seems that in HEK 293
cells, Xenopus cytoplasmic tail sequences are not sufficient to visibly
increase plasma membrane expression of the hGnRH-RI. This
observation was unexpected since studies have demonstrated that
Figure 4. Spatial localization of FLAG-human-Xenopus (HX)-GnRH-RI and FLAG-Xenopus (X)-GnRH-RI in HEK 293 cells using
organellar markers. Cells expressing FLAG-GnRH-RI (HX and X) were subjected to indirect immunofluorescent staining for the receptor (red) as well
as the nuclear membrane, endoplasmic reticulum and Golgi (all shown in green). Colocalization is seen as yellow staining. Column A: receptor alone;
Column B: receptor + Hoescht; Column C: organelle marker (lamin A/C, calnexin or GM130) + receptor; Column D: receptor + organelle marker.
Column letters and roman numerals used as a coordinate system. HX-GnRH-RI immunoreactivity co-localized with the nuclear marker, lamin A/C, as
seen by the yellow staining (I-D, arrow) as well as the endoplasmic reticulum marker, calnexin (II-D). Less colocalization was seen between the
receptor and the Golgi, as shown by less yellow staining (III-D). X-GnRH-RI immunoreactivity strongly localized to the plasma membrane (yellow
arrowheads) and weakly in cytoplasm. No visual co-localization detected with lamin A/C (IV-D, arrow), calnexin (V-D) or Golgi (VI-D). Scale bar=10 mm.
doi:10.1371/journal.pone.0011489.g004
Figure 5. Effect of GnRH stimulation on Histone 3 acetylation/phosphorylation levels in isolated nuclei from HEK 293 transiently
transfected with FLAG-GnRH-RI. (A) Purity assessment of nuclei preparations used in functional assays by bright field microscopy and Western
blotting. Left panel: Photomicrograph of a typical nuclei preparation following trypan blue staining. Scale bar=10 mm. Insert: digital magnification of
a single nucleus showing the presence of nucleoles (arrow). Right panel: Immunodetection of the membrane and nuclear markers clathrin and lamin
A/C respectively in membrane and isolated nuclei fractions from FLAG-GnRH-R-transfected HEK 293 cells. (B) Time course of Histone H3-Lys9/Lys14
acetylation and -Ser10 phosphorylation in GnRH-stimulated nuclei by Western blot analysis. A representative Western blot is shown. Densitometric
values of acetylated and phosphorylated Histone H3 levels were normalized to those of total Histone H3 and the relative intensity ratios were
expressed in-fold increase over time zero. Data are means 6 S.E.M of four independent experiments. *P,0.05 vs control time zero. Statistical analyses
performed using one-way ANOVA followed by Dunnet’s ad hoc test.
doi:10.1371/journal.pone.0011489.g005
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expression of GPCRs [50,51], including that of the human
GnRH-RI [26]. The differences observed in our HEK 293 cell-
based study compared to the MCF7 cell-based study by Sedgley
et al. [26] suggests that nuclear localization might be cell type-
dependent. This conclusion is in full agreement with those of Finch
et al. [52] who show variations in surface expression of the human
GnRH-RI and chimeric HX-GnRH-RI among various cell lines
reported to endogenously express GnRH-RI.
While it is not definite proof, failure to observe a strong and
frequent nuclear localization of the overexpressed Xenopus FLAG-
GnRH-R strengthens the conclusion that FLAG-hGnRH-RI is
not localized to the nuclear membrane due to its overexpression.
This idea is further supported by the earlier observation that
overexpression of the well-established nuclear GPCR, (FLAG-
tagged) mGluR5a, is localized to the nuclear membrane while
overexpression of the (FLAG-tagged) b2AR, a GPCR determined
not to be nuclear localized, is only detected at the plasma
membrane.
While our results clearly indicate that GnRH-RI is expressed at
the nuclear membrane, our study could not report on the precise
orientation of the receptor at the nuclear membrane. In the case of
the nuclear membrane localized EP1 receptor, the authors show
by electron microscopy that the receptor is located at both the
inner and outer nuclear membranes [43]. In both locations, the
receptor would have easy access to its ligand since the prostanoid
synthesis enzymes are located at both the inner and outer nuclear
membranes [53]. In the case of nuclear membrane localized
mGluR1a and 5a, it is reported that the receptors are oriented
with their N-terminal, ligand-binding domain within the lumen of
the nuclear envelope; hence, agonists must cross both the plasma
and nuclear membranes to access binding domains [17,54]. In
addition to other mechanisms that may exist, ligand activation of
nuclear mGluRs expressed in HEK 293 cells is achieved via
endogenous sodium-dependent transporters and cystine glutamate
exchangers that mediate the rapid delivery of quisqualate or
glutamate into the cell and into the nuclear lumen [17,54]. With
respect to the activation of GnRH-RI, extracellular GnRH might
also be routed to the nuclear membrane employing a similar
mechanism as described for the mGluRs. In addition, since
cytotrophoblasts, such as HTR-8/SVneo, express both GnRH-RI
and its ligands [1,55], it remains a possibility that ligands produced
intracellularly can somehow be routed to the nuclear membrane to
cause an activation of GnRH-RI and thus trigger off an intracrine
signaling pathway.
Our clear demonstration that GnRH-RI is expressed strongly at
the nuclear membrane is a powerful finding as it raises questions
about its function at this location. Recently, members of our
collaborative group demonstrated that the nuclear bradykinin B2
receptor positively regulates H3 acetylation [20] leading us to
explore the possibility that GnRH-RI also regulates histone H3
acetylation. Our results showed that it does. Additionally, we also
showed that nuclear GnRH-RI also potentiates histone phosphor-
ylation; the first demonstration that a nuclear GPCR can regulate
H3 phosphorylation. Overall, our results indicate that GnRH-RI
might play a more direct role in regulating gene expression than
previously appreciated and while it was not within the scope of the
present study our ongoing studies are aimed at determining which
genes are regulated by nuclear GnRH-RI. Our present finding
that the human GnRH-RI receptor is a functional nuclear GPCR
opens up many exciting possibilities on novel cellular functions
associated with this unique and clinically important GPCR and
confirms the significance of findings first made three decades ago
[21].
Materials and Methods
Materials
Restriction enzymes were obtained from Promega (Madison,
WI, USA) and New England Biolabs Inc. (Pickering, ON,
Canada). HEK 293 cells were from American Type Culture
Collection (ATCC, Manassas, VA, USA). HTR-8/SVneo cells
were a gift from Dr. Peeyush Lala from the University of Western
Ontario. Fetal bovine serum (FBS), collagen, rabbit anti-FLAG
antibody and Buserelin were purchased from Sigma Aldrich Inc.
(Oakville, ON, Canada), mouse anti-lamin A/C, and mouse anti-
calnexin from AbCam (Cambridge, MA, USA), mouse anti-
GM130 from Transduction Laboratories (BD Biosciences, Mis-
sissauga, ON, Canada), murine anti-clathrin monoclonal antibody
from Santa-Cruz Biotechnology (Santa-Cruz, CA, USA), rabbit
anti-Histone H3 and rabbit anti-phospho-Histone H3 (Ser10)
polyclonal antibodies from Cell Signaling (Danvers, MA, USA)
and rabbit anti-acetyl-Histone H3 polyclonal (Lys9 and Lys14)
antibody from Upstate Biotechnology (Lake Placid, NY, USA).
Secondary antibodies conjugated to Alexa Fluors, Hoechst dye,
pcDNA3.1/Hygro(+) vector, media and media supplements were
acquired from Invitrogen (Burlington, ON, Canada). Quisqualate
was from Tocris Biosciences (Avonmouth, Bristol, UK). All other
biochemical reagents and culture products were purchased from
BioShop, Fisher Scientific and VWR.
WT and mutant GnRH-RI expression constructs
A 987-bp cDNA fragment containing the complete coding
sequence of human GnRH-RI (accession number NM_000406.2)
was obtained by RT-PCR from the QUICK-Clone
TM cDNA
library (Clontech Laboratories Inc., CA, USA). The FLAG
sequence was introduced at the amino terminus of hGnRH-RI
by PCR. FLAG-hGnRH-RI was then cloned into the pcDNA3.1/
Hygro(+) vector using Nhe1 and Not1 sites. The untagged receptor
was created by inserting an EcoRI site with a Kozak sequence
between the FLAG tag and hGnRH-RI by PCR and then
subcloning hGnRH-RI into the pcDNA 3.1 Neo vector using
EcoRI and Not1. Human GnRH-RI-GFP was made as previously
reported [30,56].
To create the NLS deletion mutant, K191deletion mutant,
K191E mutant, FLAG-hGnRH-RI was subjected to site-directed
mutagenesis using the QuickChange kit following manufacturer’s
instructions (Stratagene, CA, USA). The putative NLS deletion
mutant was created by performing two sequential deletions; first
removing K66 and K67, followed by the deletion of E68, K69,
G70, K71 and K72. The following oligonucleotides were used:
Putative NLS deletion mutants:
K66del/K67del FWD CTTCAGAAGTGGACACAGDGA-
GAAAGGGAAAAAGCTC
K66del/K67del REV GAGCTTTTTCCCTTTCTCDCTG-
TGTCCACTTCTGAAG
E68del/K69del/G70del/K71del/K72del FWD GTTGAAA-
CTTCAGAAGTGGACACAGDCTCTCAAGAATGAAGC
E68del/K69del/G70del/K71del/K72del REV GCTTCATT-
CTTGAGAGDCTGTGTCCACTTCTGAAGTTTCAAC
The lysine 191 mutants were created in a single mutagenesis
reaction using the following oligonucleotides:
Lysine 191 mutants:
K191E FWD GCAGACAGCTCTGGACAGACAGAAGT-
TTTCTCTCAATGTG
K191E REV CACATTGAGAGAAAACTTCTGTCTGTC-
CAGAGCTGTCTGC
K191deletion FWD GCTCTGGACAGACADGTTTTCTCT-
CAATGTGTAACACAC
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A 984-bp cDNA fragment containing the complete coding
sequence of mouse GnRH-RI (accession number NM_010323.1)
was isolated by RT-PCR using RNA from the pituitary of a female
129/Sv mouse (Charles River). Bam HI and Not I sites were cloned
onto the 39 and 59 end of the cDNA construct, respectively. To
create the FLAG-tagged mouse GnRH-RI construct, the human
GnRH-RI was removed from the FLAG-pcDNA 3.1 Hygro+
vector using BamHI and NotI and the mouse GnRH-RI ORF was
ligated in.
An 1107 bp fragment corresponding to the type I Xenopus laevis
GnRH-R open reading frame (accession number AF172330) and
an 1149 bp chimeric fragment corresponding to the first 326
amino acids of the type I human GnRH-R (978 bps) fused to 56
amino acids corresponding to the type I Xenopus GnRH-R tail
sequences (171 bps) were subcloned from the pCR3 vector
(Invitrogen)[57], FLAG-epitope tagged on their N-terminus and
cloned as a NheI-NotI fragment into a home-made cloning vector
based on the pEGFP (Clontech) vector backbone.
The sequence integrity of all constructs described in this study
was verified for sequence integrity by nucleotide sequencing.
Cell culture and Immunofluorescence
HEK 293 cells were cultured in MEM supplemented with 10%
(v/v) FBS, 1% (v/v) non-essential amino acids and gentamicin
(5 mg/ml). HTR-8/SVneo cells were maintained in RPMI
supplemented with 10% FBS, 1% non-essential amino acids, 1%
glutamax, 1% sodium pyruvate and 1% penicillin/streptomycin
(v/v). Both cell lines were maintained at 37uC in a humidified
atmosphere containing 5% CO2. HEK 293 cells were transiently
transfected with 5 mg of DNA using a modified calcium phosphate
method as previously described [58] or using the ExGen 500
transfection reagent (MBI Fermentas, Canada). After transfection
(18 h), the cells were incubated with fresh medium, allowed to
recover for 6 hours and reseeded onto 18 mm collagen-coated
glass coverslips. Cells were allowed to grow an additional 18 h
prior to experimentation. HTR-8/SVneo cells were transiently
transfected with 10 mg of DNA by electroporation using the Bio-
Rad Gene Pulser Xcell System with 0.2 mm electroporation
cuvettes (BioRad) and the CHO preset protocol. Post transfection,
cells were allowed to recover for 24 hours before being plated on
18 mm collagen coated glass coverslips in 12 well plates. 42–
44 hours post-transfection, both HTR-8/SVneo and HEK 293
cells were washed twice with Hanks’ balanced salt solution (HBSS:
1.2 mM KH2PO4, 5 mM NaHCO3, 20 mM HEPES, 11 mM
glucose, 116 mM NaCl, 4.7 mM KCl, 1.2 mM MgSO4, 2.5 mM
CaCl2, pH 7.4) and either stimulated [100 nM Buserelin for
GnRH-RI and 100 mM Quisqualate for mGluR5a] for two hours
or left untreated. Cells were fixed and permeabilized using 4%
formaldehyde and 0.2% Triton-X in HBSS for 20 minutes,
washed 4 times with HBSS and blocked with HBSS-3% BSA for
30 minutes before the addition of primary antibody. Cells were
incubated with primary antibody overnight at 4uC at the following
concentrations: polyclonal anti-FLAG 1:2000, monoclonal anti-
calnexin 1:100 (to detect endoplasmic reticulum), monoclonal anti-
GM130 1:100 (to detect the Golgi apparatus), monoclonal anti-
lamin A/C 1:10 (to detect the inner nuclear membrane).
Coverslips were then washed 4 times with HBSS and blocked
for an additional 30 minutes in HBSS containing 3% BSA before
incubation with secondary antibody for 45 minutes at room
temperature. Goat anti-mouse antibody conjugated to AlexaFluor
488 was used at a dilution of 1:250, while goat anti-rabbit antibody
conjugated to AlexaFluor 568 was used at 1:1200. Cells were
washed 4 times with HBSS and then counter-stained using
Hoechst at 1:50000 (v/v) for 7 minutes to detect DNA. After 4
additional washes with HBSS, cells were mounted onto glass slides
and allowed to dry overnight at room temperature. Confocal
analysis was performed on an Olympus Fluoview 1000 laser
scanning confocal microscope using either the 60X Plan
Apochromat 1.42 oil objective or the 100x Plan superapochromat
1.4 Oil objective. Colocalization studies were performed using
multiple excitation (405, 488, 559) and emission (band pass 425–
475, 500–545 nm and 575–675 nm for Hoechst, AlexaFluor 488
and AlexaFluor 568 respectively) filter sets. Multi-colour images
were acquired in the sequential acquisition mode to avoid cross-
excitation.
Nuclei isolation for immunofluorescence studies
Nuclei were isolated using the Sigma Nuclei EZ Prep Nuclei
Isolation Kit using a modified protocol. In brief, nuclei were
isolated from HEK 293 cells expressing FLAG-GnRH-RI, FLAG-
mGluR5a or FLAG-b2AR approximately 42–44 hours post-
transfection. Cells were stimulated with agonist for 2 hours or left
untreated, washed twice with ice cold PBS and then lysed using 15
strokes of a 15 ml Dounce homogenizer using the tight pestle. The
lysate was mixed with a 1.8 M sucrose solution and then layered
over 10 ml of 1.8 M sucrose solution in a 40 ml Beckman
centrifuge tube (Beckman Coulter Inc., Fullerton, CA, USA).
Tubes were spun at 12900 rpm in a swinging bucket rotor for 85
minutes to pellet the nuclei. The supernatant was removed and
nuclei were washed and resuspended in storage buffer (provided).
A sample of nuclei was plated on 18 mm collagen coated
coverslips in 12 well plates and fixed and immunostained as
described above.
Nuclei isolation for functional studies
Nuclei isolation technique was adapted from [59]. HEK 293
cells were washed with ice-cold PBS (10 ml/20 cm plate), gently
scraped on ice in 5 ml PBS/1 mM EDTA and centrifuged at
500 g for 5 min at 4uC. Pelleted cells were resuspended in 1 ml
hypotonic lysis buffer (10 mM Tris-HCl pH 7.4, 5 mM KCl,
3 mM MgCl2 and protease inhibitor cocktail (Roche), allowed to
swell on ice for 1 h then homogenized (100 gentle strokes) using a
Dounce tissue grinder (tight pestle; Bellco Glass). Nuclear samples
were diluted to 15 ml with lysis buffer, centrifuged (800 g, 8 min
at 4uC) and resuspended in 5 ml stimulation buffer (20 mM Hepes
pH 7.4, MgCl2 3 mM, KCl 20 mM, CaCl2 200 nM, ATP 25 mM
and glycerol 10%) for visual inspection and counting of nuclei.
Protein concentration was determined using the BCA method.
Nuclei were stored at 280uC unless otherwise stated. Purity of
subcellular fractions was further substantiated by means of
immunological methods using the specific organelle marker
antigens clathrin (plasma membrane) (1:250 dilution) and lamin
A/C (nuclei) (1:100 dilution).
Acid extraction of histone and Western blotting of
Histone H3
HEK 293 nuclei (6–10610
6 nuclei/assay) were resuspended in
stimulation buffer (20 mM Hepes pH 7.4, MgCl2 3 mM, KCl
20 mM, CaCl2 200 nM, ATP 25 mM and glycerol 10%), allowed
to pre-equilibrate at 37uC for 15 min with gentle shaking, then
challenged with 100 nM of GnRH for 0, 5, 15 and 30 min.
Reaction was terminated by freezing samples in liquid nitrogen.
Acid extraction of histones was performed according to [20].
Briefly, nuclei were resuspended in lysis buffer (Tris–HCl 50 mM
pH 8, MgCl2 5 mM, KCl 25 mM containing HCl 0.2 N, 1 mM
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EDTA-free protease inhibitor cocktail), and incubated on ice for
30 min. After centrifugation at 11,000 g for 15 min, 1 ml of cold
acetone was added to the supernatant and placed at 220uC for
4 h. Precipitated proteins were collected by centrifugation at
11,000 g for 15 min. Pellets were washed twice with cold acetone,
dried and resuspended in 25 ml of water containing 1 mM NaF,
1m MN a 3VO4, 2.5 mM sodium butyrate and protease inhibitors
cocktail. Acid proteins including histones were quantified using the
BCA method and 5 mg were loaded on a 15% polyacrylamide gel
and analyzed by Western blotting using an anti-acetylated
(1:3,000), anti-phosphorylated (1:5,000) or anti total histone H3
(1:2,500) antibody.
Western Blotting
Proteins were analyzed by Western blotting and immunoblots
were visualized by chemiluminescence using an ECL kit (GE).
Densitometric analysis of autoradiograms was performed using
ImagePro 5.1 software.
Inositol Phosphate Formation
Inositol lipids were radiolabeled by incubating cells overnight
with 1 mCi/ml [
3H]myo-inositol in Dulbecco’s modified Eagle’s
medium. Unincorporated [
3H]myo-inositol was removed by
washing the cells with HBSS. Cells were preincubated for 1 h in
HBSS at 37uC and then preincubated in 500 ml of the same buffer
containing 10 mM LiCl for an additional 10 minutes at 37uC.
Next, the cells were incubated in either the absence or the
presence of 100 nM Buserelin for 2 hours at 37uC. The reaction
was stopped on ice by adding 500 ml of 0.8 M perchloric acid and
then neutralized with 400 ml of 0.72 M KOH, 0.6 M KHCO3.
The total [
3H]inositol incorporated into the cells was determined
by counting the radioactivity present in 50 ml of the cell lysate.
Total inositol phosphate was purified from the cell extracts by
anion exchange chromatography using Dowex 1-X8 (formate
form) 200–400 mesh anion exchange resin. [
3H]Inositol phosphate
formation was determined by liquid scintillation using a Wallac
LKB 1211 RackBeta liquid scintillation counter. The means 6
S.E. are shown for the number of independent experiments
indicated in the figure legends. GraphPad Prism software was used
to analyze data for statistical significance. Statistical significance
was determined by Student’s t-test or one-way analysis of variance
followed by Dunnet’s ad hoc test. P-values ,0.05 were considered
to be significant.
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